Neuprex recombinant bactericidal/permeability-increasing: XOMA began a fourth Phase I/II trial

The study is a 24-patient, open-label, dose-escalating multi-center trial. XOMA expects to follow the current study with a randomized, placebo-controlled trial, beginning by the end of 1996. ...